China’s biotechnology industry is developing rapidly: in 2024, almost 30% of the major pharmaceutical processes resulted in the participation of Chinese companies, and in 2020, this indicator was less than 5%. Reducing costs, accelerating clinical research and the return of leading scientists to China contributed to this growth. Although most Chinese innovations aim to improve existing drugs, not entirely in the creation of new ones, their effects are increasing.
Large pharmaceutical companies are going to China to licens drugs. For example, Merck and Astrazeneca have made much less transactions with Chinese companies in the United States for obesity supply in the United States. This is useful for patients and large pharmaceutical companies, but intervenes for American biotechnological companies that are difficult to compete.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
